• BVI’s Leos system has been used clinically for the first time at New York Eye and Ear Infirmary, marking the first academic institution to acquire and utilize the system in the New York tri-state area.

• Leos is the first and only FDA-cleared laser system with advanced digital endoscopic visualization for ab interno intraocular pressure reduction.

WALTHAM, Mass., May 14, 2026 — BVI, a global ophthalmic device company, today announced that New York Eye and Ear Infirmary (NYEE) of Mount Sinai is the first eye center in New York City and the Tri-State-Area to use Leos in a clinical setting, and successfully treated one patient with the technology on May 6, 2026.

Leos is the first and only FDA-cleared digital endoscopy and laser system designed to reduce intraocular pressure through a minimally invasive ab interno approach while providing advanced visualization of the eye’s internal anatomy. Leos received FDA 510(k) clearance in April 2025.

“NYEE has long stood at the forefront of ophthalmic care, education and innovation, and we are honored that one of the world’s most respected eye institutions is among the earliest adopters of Leos,” said Jim Hollingshead, president and chief executive officer of BVI. “This milestone reflects exactly why BVI invested in Leos: to bring surgeons a modern, intuitive laser endoscopy platform that enhances visualization, supports workflow efficiency, and expands minimally invasive options for patients with glaucoma.”

“At New York Eye and Ear Infirmary of Mount Sinai, our mission is to lead in the incorporation of advanced technologies that enhance patient care, surgical precision, and clinical education,” said James C. Tsai, MD, MBA, president of NYEE, Chair of the Department of Ophthalmology for Mount Sinai Health System. By bringing this next-generation digital endoscopy and laser platform to NYEE, we are reconfirming our commitment to offering our surgeons and patients access to innovations and devices that can help advance the future of glaucoma treatment.”

Luis Silva, MD, an ophthalmologist at NYEE who trained on Leos at the recent American Glaucoma Society meeting, performed the first Leos ECP procedure, “As a glaucoma surgeon with experience in ECP, I was pleased to witness a significant improvement in this technology, with the surgeon now taking complete control of visualization of the ciliary body processes,” Dr. Silva said. “Leos’ visualization, image stability, and intuitive controls support a more controlled surgical experience and may help surgeons approach ECP with greater confidence and consistency.”

Leos was designed to meet the evolving needs of surgeons treating a broad range of glaucoma patients, including those in earlier stages of disease, and is powered by advanced endoscopic visualization capabilities. When paired with the single use, sterile VueProbe®, the system’s advanced auto functions and workflow-focused design are intended to enhance the ECP procedure for surgeons and operating room staff while supporting integration with cataract procedures.

“Leos is an important part of BVI’s broader commitment to advancing eye surgery through practical innovation,” Hollingshead said. “Partnering with leading institutions like NYEE helps ensure that meaningful technologies reach the surgical teams who are shaping the next era of ophthalmic care.”

About BVI

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients’ vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

To learn more about BVI and its mission to advance the future of vision, visit https://www.bvimedical.com

***

Press Contact

David Chavez Global Communications Lead [email protected] +1 (857) 869 8706

• BVI continues to grow and build a strong company culture based on simplicity, transparency and an entrepreneurial mindset.
• BVI opens an office in Krakow (Poland), welcoming over 50 employees

Waltham, MA, September 16th, 2024 – BVI, one of the fastest-growing, diversified companies in ophthalmology, is proud to announce the creation of its new BVI Poland entity, opening a new office in Krakow. This September, BVI celebrated the grand opening for local employees, their leaders, and members of the Leadership Team.

Driving efficiency and scalability

BVI consistently looks for ways to drive efficiency and scalability through process improvement, system enhancement, and workload consolidation. This approach has led the company to build new capabilities and scale that the organization didn’t have previously.

Krakow will be a new hub for a Centre of Excellence and is a great location for talent. This modern office welcomes over 50 employees from several departments: Finance, Customer Operations, Regulatory Affairs, Quality Assurance, HR, and Talent Acquisition. Teams of experts with strong language capabilities will take on business operations/back office duties, emphasising simplicity and speed in action for the company.

The BVI entity in Poland will further strengthen BVI’s footprint in Europe.

Andy Dawson, CPO said: “It is incredibly exciting to see BVI continue to grow and to see the excitement that the team continues to bring. The talent we’ve been able to attract is outstanding and will make an immediate impact as part of our global organization.”

Todd Patriacca, CFO said: “”I’m incredibly excited about opening our Poland location and establishing a base for collaboration. The fresh perspectives and expertise our team brings will drive impactful process improvements, setting us on a path to greater efficiency and success.”

Devang Shah, SVP Business Operations, RA and QA said: ““The opening of our Krakow office represents a key milestone in BVI’s journey towards greater operational excellence. This site will not only enhance our operational capabilities but also embody our commitment to a seamless customer experience. The talented team we’ve assembled here will be instrumental in driving forward our strategic goals and reinforcing our presence globally.”

About BVI

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients’ vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

For further enquiries or to speak to a BVI representative, please email Andrew Dawson, Chief People Officer & Head of BVI Corporate Communications: [email protected]

BVI to Launch New SERENITY and SERENITY Toric Premium Monofocal IOLs, Delivering an Extended Range of Vision to More Patients, at the 2024 ESCRS

• Non-diffractive IOLs SERENITY and SERENITY Toric are the second generation of BVI’s original, innovative ISOPURE premium monofocal IOL launched in 2019.
• These IOLs incorporate patented ISOFOCAL optic technology to provide both distance vision and intermediate vision.¹ The ground-breaking double c-loop POD platform is specifically engineered to deliver precise astigmatism correction and stable IOL positioning.²
• These lenses are designed to meet the growing demand for intermediate-optimized IOLs, which are projected to see a 15% CAGR. ³

Waltham, MA, September 3, 2024 – BVI today unveiled its latest innovations: SERENITY and SERENITY Toric premium monofocal IOLs. These non-diffractive, aspheric IOLs are the second generation of BVI’s pioneering ISOPURE family, first introduced in 2019. Utilizing patented ISOFOCAL optic technology to elegantly balance Depth of Focus (DoF) and image quality, these lenses provide far vision equal to a monofocal but with good intermediate vision up to 66 cm.¹

Continuing the IOL Innovation Legacy

Since the launch of ISOPURE in 2019, BVI has remained committed to providing innovative solutions for patients seeking an uncompromised, extended range of vision. The SERENITY series maintains the simplicity of a monofocal IOL while incorporating ISOFOCAL technology to deliver spherical aberration correction across the entire optic diameter and customize the level of spherical aberration per dioptric power.

The SERENITY Toric model benefits significantly from the maneuverability of the double C-loop POD platform. This platform is exclusive to BVI and allows the IOL to be rotated clockwise or counterclockwise to align the cylinder with the axis. For astigmatic patients, the POD platform delivers a toric IOL that remains stable in the capsular bag,² with outcomes accurately predicted by BVI’s toric calculator.

Mr. Sheraz DayaMD FACP FACS FRCS(Ed) FRCOphth (Centre For Sight, UK), one of the first surgeons to implant SERENITY, commented, “It is wonderful to see this Increased range of focus lens (IROF) on the same platform as the Finevision with 4 C loop haptics. I look forward to the Toric version as well which I know will be very stable with no rotation.”

“As we launch the second-generation SERENITY and SERENITY Toric IOLs, BVI views this IOL as potentially a game-changer when it comes to standard of care for monofocal procedures,” saidShervin Korangy, President and CEO of BVI. “Our portfolio includes a wide range of IOLs, meticulously designed from material to haptics to optics to provide the optimal outcome without the burden of retro-fitting legacy predicate devices.”

Global Launch Schedule

SERENITY and SERENITY Toric will have full commercial availability in CE-accepting markets in 2025⁴.

About BVI

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving the vision of patients. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

For further enquiries or to speak to a BVI representative, please email Andrew Dawson, Head of BVI Corporate Communications: [email protected]

References

1. Bernabeu-Arias G, Beckers S, RincónRosales JL, Tañá-Rivero P, Bilbao-Calabuig R. Visual Performance at Different Distances After Implantation of an Isofocal Optic Design Intraocular Lens. J Refract Surg. 2023 Mar;39(3):150-157.
2. Robert Edward T Ang, Pedro Tañá-Rivero, Francisco Pastor-Pascual, Pavel Stodulka, Manfred Tetz, Isaak Fischinger. Visual and Refractive Outcomes After Bilateral Implantation of a Biconvex Aspheric Toric Monofocal Intraocular with a Double C-Loop Haptic Design. Clinical Ophthalmology 2023:17 2765–2776.
3. 2024 IOL Market Report, Market Scope, P. 188
4. Not Available for Sale in the United States

It’s 4 for 4 in 2024!

• BVI continues to grow and build a strong company culture based on simplicity, transparency and an entrepreneurial mindset.
• BVI has re-certified Great Place to Work in the US, France, and the Netherlands for several years in a row, and certified first time around in Mexico

WALTHAM, Mass., August 14, 2024 — BVI Medical (BVI), one of the fastest-growing, diversified company in ophthalmology, is proud to have been Certified™ Great Place to Work® Certified™ for the past four years in the U.S., and also in France and the Netherlands. For the first time, BVI was also recognized in Mexico.

The prestigious award is based on what current employees say about their experience working at BVI. With 78% participation on average across all four locations this year, 83% of employees said BVI is a great place to work.

BVI attributes this accolade to the company’s focus on building a strong company culture based on simplicity, transparency, and an entrepreneurial mindset.

We are thrilled to become Great Place to Work-Certified™ as we consider employee experience a top priority every day,” said Shervin Korangy, President and CEO of BVI. “The questionnaire has highlighted what makes BVI unique and our leadership teams are proud to see that the aspects they’ve worked on have improved and our people have seen the positive impact of their actions.”

This past June, BVI celebrated the certification at its four office locations across the U.S., France, the Netherlands, and Mexico, with onsite activities, and online events.

About BVI

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving the vision of patients. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors. Our trusted brands include Knives and Blades, Cannulas, Single-Use Instruments, Vitreoretinal Surgical Products and Premium IOLs.

At BVI, we seek engaged, innovative, and talented professionals, interested in growing their careers within the ophthalmic industry. We want to work with individuals who are looking to constantly learn, collaborate and advance eye health across the globe. 

For further enquiries, visit our career page or email Andrew Dawson, Chief People Officer: [email protected]

About Great Place to Work®
Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees worldwide and used those deep insights to define what makes a great workplace: trust. Their employee survey platform empowers leaders with the feedback, real-time reporting and insights they need to make data-driven people decisions. Everything they do is driven by the mission to build a better world by helping every organization become a great place to work For All™.

About Great Place to Work Certification™
Great Place to Work® Certification™ is the most definitive “employer-of-choice” recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place to Work-Certified.

About the survey

Great Place to Work® is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation.The survey measures employees’ perception by asking 60 questions, structured out of 5 dimensions around Trust: Credibility, Respect, Fairness, Pride, and Camaraderie.